AMCP joined with other health care stakeholders to urge Congressional leadership to bolster Medicaid funding due to the COVID-19 public health emergency.
July 2020 News & Views includes: Doug Long to Discuss Health Care Trends and Impact of COVID-19 at AMCP Webinar, July 9 at 2pm ET; AMCP Foundation Unveils New Mission Statement, Marks 30 Year Anniversary; David Calabrese, 2020 Avey Award Recipient, Shares Insights on Career and Profession; AMCP Corporate Member Spotlight: Scipher Medicine
CMS outlining proposed changes to the calculation of best price under the Medicaid Drug Rebate Program (MDRP), particularly how manufacturers should account for value-based purchasing programs.
Read this week’s blog to learn how AMCP is taking a stand against racial injustice and starting work to translate broad goals into specific, long-term actions that improve patient outcomes and health equity among all Americans, including Black Americans, indigenous people, and people of color.
AMCP Joins Pharmaceutical Supply Chain Stakeholders to Support Access to Medications; AMCP Comments on COVID-19 Changes to Medicare Program; FDA Issues RFI on Improving the Orange Book; CMS Issues Final Medicare Part C and Part D Policy, Technical Rule
May issue includes: AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; Two Proposed Biosimilars Bills Fail to Advance
April issue includes: CARES Act Includes Changes Relevant to Managed Care Pharmacy, Substance Abuse Record Rules; HHS Authorizes Pharmacists to Order and Administer COVID19 Tests; AMCP Launches COVID19 Resource Center; AMCP Submits Comments on Proposed Medicare Advantage and Part D Rule; AMCP Comments to FDA and FTC on a Competitive Biosimilar Marketplace